Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SAJ, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A.

Mol Cancer Ther. 2020 Feb;19(2):468-478. doi: 10.1158/1535-7163.MCT-19-0466. Epub 2019 Oct 16.

2.

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.

Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I, Reschke S, van der Mey D, Granvil C.

Cancer Chemother Pharmacol. 2017 Sep;80(3):535-544. doi: 10.1007/s00280-017-3383-9. Epub 2017 Jul 11.

3.

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC.

Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12.

4.

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y.

Haematologica. 2012 May;97(5):731-8. doi: 10.3324/haematol.2011.045666. Epub 2012 Feb 7.

5.

Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.

Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW.

J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116.

PMID:
19492955
6.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyridamole in human plasma and its application in a pharmacokinetic study.

Chen M, Granvil C, Ji QC, Zhang ZY, Padval MV, Kansra VV.

J Pharm Biomed Anal. 2009 Jul 12;49(5):1241-9. doi: 10.1016/j.jpba.2009.02.017. Epub 2009 Feb 25.

PMID:
19304431
7.

Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry.

Arnold DR, Granvil CP, Ward KW, Proksch JW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 1;867(1):105-10. doi: 10.1016/j.jchromb.2008.03.025. Epub 2008 Apr 1.

PMID:
18417430
8.

Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.

Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ.

Drug Metab Dispos. 2003 May;31(5):548-58.

PMID:
12695342
9.

The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.

Yu AM, Granvil CP, Haining RL, Krausz KW, Corchero J, Küpfer A, Idle JR, Gonzalez FJ.

J Pharmacol Exp Ther. 2003 Feb;304(2):539-46.

PMID:
12538805
10.

4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.

Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ.

J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.

PMID:
12023534
11.

The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, Gonzalez FJ.

Mol Pharmacol. 2001 Dec;60(6):1260-7. Erratum in: Mol Pharmacol 2002 Jan;61(1):248.

PMID:
11723233
12.

Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites.

Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G.

Life Sci. 2000 Nov 24;68(1):109-17.

PMID:
11132240
13.
14.
15.

Enantioselective induction of cyclophosphamide metabolism by phenytoin.

Williams ML, Wainer IW, Embree L, Barnett M, Granvil CL, Ducharme MP.

Chirality. 1999;11(7):569-74.

PMID:
10423284
16.

Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.

Williams ML, Wainer IW, Granvil CP, Gehrcke B, Bernstein ML, Ducharme MP.

Chirality. 1999;11(4):301-8.

PMID:
10224657
17.

Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.

Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW.

Drug Metab Dispos. 1999 Apr;27(4):533-41.

PMID:
10101149
18.

Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers.

Ducharme MP, Bernstein ML, Granvil CP, Gehrcke B, Wainer IW.

Cancer Chemother Pharmacol. 1997;40(6):531-3.

PMID:
9332469
19.

Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.

Granvil CP, Ducharme J, Leyland-Jones B, Trudeau M, Wainer IW.

Cancer Chemother Pharmacol. 1996;37(5):451-6.

PMID:
8599868
20.
22.

Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model.

Wainer IW, Granvil CP, Wang T, Batist G.

Cancer Res. 1994 Aug 15;54(16):4393-7.

23.

Ifosfamide stereoselective dichloroethylation and neurotoxicity.

Wainer IW, Ducharme J, Granvil CP, Trudeau M, Leyland-Jones B.

Lancet. 1994 Apr 16;343(8903):982-3. No abstract available.

PMID:
7909040
24.

Metabolic fate of methyl n-butyl ketone, methyl isobutyl ketone and their metabolites in mice.

Granvil CP, Sharkawi M, Plaa GL.

Toxicol Lett. 1994 Feb 15;70(3):263-7.

PMID:
8284793
25.

Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat.

Granvil CP, Wang T, Batist G, Wainer IW.

Drug Metab Dispos. 1994 Jan-Feb;22(1):165-7. No abstract available.

PMID:
8149878
26.

Supplemental Content

Loading ...
Support Center